FTSE MIB
29.655,20 +278,46 (+0,95%) Dow Jones
35.475,31 +58,33 (+0,16%) Nasdaq
14.321,37 +39,61 (+0,28%) Nikkei 225
33.321,22 -87,17 (-0,26%) Petrolio
75,91 -0,50 (-0,65%) Bitcoin EUR
34.503,74 +301,33 (+0,88%)
AnaptysBio, Inc. (0HFQ.L)
| Chiusura precedente | 15,42 |
| Aperto | 0,00 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 265 |
| Capitalizzazione | 3,172M |
| Beta (5 anni mensile) | -0,22 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,76 |
| Prossima data utili | 28 feb 2024 - 04 mar 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAnaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023. The oral presentation will focus on ANB032’s previously reported healthy volunteer Phase 1 data and the trial-in-progress poster presentation will focus on ANB032’s Phas
- GlobeNewswire
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody, at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25. Independent medical experts and members of Anaptys senior management will discuss: PD-1 biology and rosnilim
- GlobeNewswire
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at Week 4 (primary endpoint), compared to 13.3% of patients on placebo (p=0.0131)Demonstrated favorable safety and tolerability with no SAEs, low incidence and no increase of infections vs. placebo and no cases of DRESS or Guillain-Barre in imsidolimab-treated patientsOnly one of 30 (3.3%) imsidolimab-treated patients had detectable ADA, which were non-neutralizingPlan to present comp
